Phase 1Completed

Haplo Peripheral Blood Sct In GVHD Prevention

Reduced Intensity Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Sirolimus/Mycophenolate Mofetil/RGI-2001 Based GVHD Prevention: a Pilot Study

Sponsor
Zachariah Michael DeFilipp (Academic or other)
Enrollment
25 enrolled
Conditions
GVHD; AML; ALL; MDS; MPN; CMML; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Blood Stem Cell Transplant Failure; Graft Vs Host Disease; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia
Interventions
FLUDARABINE; CYCLOPHOSPHAMIDE; TBI; Melphalan; Sirolimus; Mycophenolate mofetil; RGI-2001; CYCLOPHOSPHAMIDE
Ages
adults, older adults
Registry
NCT04473911

Full record on ClinicalTrials.gov

From the registry

This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation. * GVHD is a condition in which cells from the donor's tissue attack the organs. * RGI-2001 is an investigational treatment

Primary outcomes

  • Number of patients achieving successful donor engraftment

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Started

  5. Registered

Papers citing this trial